GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcutis Biotherapeutics Inc (NAS:ARQT) » Definitions » Days Payable

Arcutis Biotherapeutics (Arcutis Biotherapeutics) Days Payable : 511.32 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Arcutis Biotherapeutics Days Payable?

Arcutis Biotherapeutics's average Accounts Payable for the three months ended in Dec. 2023 was $12.59 Mil. Arcutis Biotherapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $2.25 Mil. Hence, Arcutis Biotherapeutics's Days Payable for the three months ended in Dec. 2023 was 511.32.

The historical rank and industry rank for Arcutis Biotherapeutics's Days Payable or its related term are showing as below:

ARQT' s Days Payable Range Over the Past 10 Years
Min: 761.87   Med: 2339.06   Max: 3916.25
Current: 931.55

During the past 7 years, Arcutis Biotherapeutics's highest Days Payable was 3916.25. The lowest was 761.87. And the median was 2339.06.

ARQT's Days Payable is ranked better than
83.61% of 714 companies
in the Biotechnology industry
Industry Median: 147.95 vs ARQT: 931.55

Arcutis Biotherapeutics's Days Payable declined from Dec. 2022 (1,645.60) to Dec. 2023 (511.32). It may suggest that Arcutis Biotherapeutics accelerated paying its suppliers.


Arcutis Biotherapeutics Days Payable Historical Data

The historical data trend for Arcutis Biotherapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcutis Biotherapeutics Days Payable Chart

Arcutis Biotherapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Payable
Get a 7-Day Free Trial - - - 3,916.25 761.87

Arcutis Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,645.60 1,241.84 1,742.75 1,170.93 511.32

Competitive Comparison of Arcutis Biotherapeutics's Days Payable

For the Biotechnology subindustry, Arcutis Biotherapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcutis Biotherapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Arcutis Biotherapeutics's Days Payable falls into.



Arcutis Biotherapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Arcutis Biotherapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

Days Payable (A: Dec. 2023 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2022 ) + Accounts Payable (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (8.827 + 11.992) / 2 ) / 4.987*365
=10.4095 / 4.987*365
=761.87

Arcutis Biotherapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

Days Payable (Q: Dec. 2023 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Sep. 2023 ) + Accounts Payable (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (13.179 + 11.992) / 2 ) / 2.246*365 / 4
=12.5855 / 2.246*365 / 4
=511.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arcutis Biotherapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Arcutis Biotherapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcutis Biotherapeutics (Arcutis Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Executives
Masaru Matsuda officer: SVP and General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Frazier Life Sciences Viii, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Larry Todd Edwards officer: Chief Commercial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patrick Burnett officer: See Remarks C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Todd Franklin Watanabe director, officer: President and CEO C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Howard G. Welgus director C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Scott L Burrows officer: Chief Financial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patricia A. Turney officer: Senior VP, Manufacturing C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
David W Osborne officer: Chief Technical Officer
Kenneth A. Lock officer: Chief Commercial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Matthew Richard Moore officer: SVP and Chief Business Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Neha Krishnamohan director 12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656